(MedPage Today) — New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive…
Source link : https://www.medpagetoday.com/meetingcoverage/auavideopearls/115825
Author :
Publish date : 2025-05-30 17:50:00
Copyright for syndicated content belongs to the linked Source.
